113 related articles for article (PubMed ID: 1341474)
1. Cost of antibiotic therapy for community-acquired pneumonia.
Trevisani L; Putinati S; Sartori S; Potena A
Eur J Med; 1992 Oct; 1(6):380-1. PubMed ID: 1341474
[No Abstract] [Full Text] [Related]
2. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.
Marras TK; Nopmaneejumruslers C; Chan CK
Am J Med; 2004 Mar; 116(6):385-93. PubMed ID: 15006587
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
[TBL] [Abstract][Full Text] [Related]
4. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.
Houck PM; Bratzler DW; Nsa W; Ma A; Bartlett JG
Arch Intern Med; 2004 Mar; 164(6):637-44. PubMed ID: 15037492
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacoeconomic estimation of cost of community acquired pneumonia therapy].
Kulidzhanov AIu; Sirotko II; Koriakin PM; Korchazhkin VS
Voen Med Zh; 2001 Jan; 322(1):50-2. PubMed ID: 11219929
[No Abstract] [Full Text] [Related]
6. Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.
Stein GE; Mantz SL
Hosp Pharm; 1995 Feb; 30(2):132-4, 137. PubMed ID: 10140526
[TBL] [Abstract][Full Text] [Related]
7. [Pneumonia in the antibiotic era].
He L
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Apr; 22(4):197-8. PubMed ID: 11775912
[No Abstract] [Full Text] [Related]
8. Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in The Netherlands.
Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM
Clin Microbiol Infect; 2005 Dec; 11(12):992-8. PubMed ID: 16307553
[TBL] [Abstract][Full Text] [Related]
9. [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia].
Bermejo Vicedo T; Torralba Arranz A; Hidalgo Correas FJ; Millán Santos I; Rodríguez Morradan B
Farm Hosp; 2004; 28(1):29-35. PubMed ID: 15012176
[TBL] [Abstract][Full Text] [Related]
10. Costs of treating lower respiratory tract infections.
Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
[TBL] [Abstract][Full Text] [Related]
11. Management of community-acquired pneumonia by trained family general practitioners.
Potena A; Simoni M; Cellini M; Cartabellotta A; Ballerin L; Piattella M; Putinati S
Int J Tuberc Lung Dis; 2008 Jan; 12(1):19-25. PubMed ID: 18173872
[TBL] [Abstract][Full Text] [Related]
12. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Halpern MT; Cifaldi MA
Clin Infect Dis; 2004 Jul; 39(1):144-5; author reply 145-6. PubMed ID: 15206068
[No Abstract] [Full Text] [Related]
13. [Short course antibiotherapies in community-acquired pneumonia].
Bulbul Y; Ozlu T
Tuberk Toraks; 2008; 56(3):344-52. PubMed ID: 18932039
[TBL] [Abstract][Full Text] [Related]
14. The effect of implementing the British Thoracic Society community-acquired pneumonia guidelines on antibiotic prescribing and costs in a UK teaching hospital.
Barlow G; Nathwani D; Davey P
Clin Microbiol Infect; 2006 May; 12(5):498-500. PubMed ID: 16643534
[No Abstract] [Full Text] [Related]
15. Community-acquired pneumonia: is it time to shorten the antibiotic treatment?
Esposito S; Fiore M
Expert Rev Anti Infect Ther; 2007 Dec; 5(6):933-8. PubMed ID: 18039078
[No Abstract] [Full Text] [Related]
16. Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia.
Opmeer BC; El Moussaoui R; Bossuyt PM; Speelman P; Prins JM; de Borgie CA
J Antimicrob Chemother; 2007 Nov; 60(5):1131-6. PubMed ID: 17827142
[TBL] [Abstract][Full Text] [Related]
17. Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia.
Sabes-Figuera R; Segú JL; Puig-Junoy J; Torres A
Eur J Health Econ; 2008 Feb; 9(1):23-32. PubMed ID: 17221181
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia.
Yu KT; Wyer PC
Ann Emerg Med; 2008 May; 51(5):651-62, 662.e1-2. PubMed ID: 18272253
[TBL] [Abstract][Full Text] [Related]
19. Community-acquired pneumonia guidelines: Peering back through the looking glass...clearly?
Peterson MW; Hornick DB
Am J Med; 2004 Nov; 117(10):799-800. PubMed ID: 15541330
[No Abstract] [Full Text] [Related]
20. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
